贝达药业：2025年前三季度，公司实现营业收入27.17亿元

Core Viewpoint - The company reported a significant increase in revenue and EBITDA for the first three quarters of 2025, indicating positive growth trends in its financial performance [2] Financial Performance - The company achieved an operating revenue of 2.717 billion yuan, representing a year-on-year growth of 15.90% [2] - The company's EBITDA reached 860 million yuan, reflecting a year-on-year increase of 20.15% [2] - Net profit did not grow in tandem with EBITDA due to factors such as depreciation and amortization [2] Future Outlook - The company anticipates continued improvement in revenue as its drug promotion strategies are implemented, which will positively impact financial metrics [2]